Cathie Wood’s ARK Invest Buys Over 750,000 Shares of Ginkgo Bioworks
One of Cathie Wood's ARK Invest exchange-traded funds bought over 750,000 shares of Ginkgo Bioworks on December 14.
One of the ARK Invest exchange-traded funds run by ETF star Cathie Wood made a huge buy on Tuesday. Specifically, this fund bought roughly $7.3 million worth of Ginkgo Bioworks Holdings Inc. (NYSE: DNA), as the prices of this fund was down slightly on Tuesday.
[in-text-ad]
ARK Innovation ETF (NYSEARCA: ARKK) bought 764,703 shares of Ginkgo Bioworks. At Tuesday’s closing price, this would have valued the sale at roughly $7.3 million. Even though this is a small fraction of their total holdings, every little bit counts. The Innovation ETF is down over 23% in the past year.
[nativounit]
Check out all the ARK Invest purchases for Tuesday as well:
| Fund | Ticker | Name | Shares |
|---|---|---|---|
| ARKF | TCSLI | TCS GROUP | 73,600 |
| ARKF | DSYSJ | DISCOVERY | 29,478 |
| ARKG | VCYT | VERACYTE | 45,700 |
| ARKG | SLGC | SOMALOGIC | 187,013 |
| ARKG | SDGR | SCHRODINGER | 12,216 |
| ARKG | QSI | QUANTUM-SI | 51,318 |
| ARKG | PSNL | PERSONALIS | 100,496 |
| ARKG | NTLA | INTELLIA THERAPEUTICS | 20,655 |
| ARKG | MASS | 908 DEVICES | 20,047 |
| ARKG | FATE | FATE THERAPEUTICS | 196,581 |
| ARKG | ACCD | ACCOLADE | 116,240 |
| ARKG | BLI | BERKELEY LIGHTS | 44,000 |
| ARKK | SSYS | STRATASYS | 72,471 |
| ARKK | NVTA | INVITAE | 18,000 |
| ARKK | NTLA | INTELLIA THERAPEUTICS | 8,433 |
| ARKK | MTLS | MATERIALISE | 32,775 |
| ARKK | DNA | GINKGO BIOWORKS | 764,703 |
| ARKQ | XPEV | XPENG | 97,697 |
| ARKQ | VUZI | VUZIX | 32,182 |
| ARKQ | BLDE | BLADE AIR MOBILITY | 44,068 |
| ARKW | COIN | COINBASE GLOBAL | 11,761 |
| ARKW | EDR | ENDEAVOR GROUP | 177,885 |
| ARKW | VCYT | VERACYTE | 50,910 |
| ARKW | ROKU | ROKU | 7,188 |
| ARKX | AVAV | AEROVIRONMENT | 16,273 |
| ARKX | GRMN | GARMIN | 8,728 |
| ARKX | MYNA | MYNARIC | 4,707 |
Catherine Wood, the CEO and CIO of ARK Investment Management, is a minority and nonvoting shareholder of 24/7 Wall St.
[recirclink id=1013324][wallst_email_signup]
Contact [email protected] for any questions or corrections.
Chris Lange is a financial and geopolitical writer with more than a decade of experience covering a myriad of topics. He has published thousands of articles for 24/7 Wall St., with past coverage focused heavily on stocks, IPOs, healthcare, defense, global affairs, and technology.
His work has been quoted, or referenced by a number of outlets including Business Insider, USA Today, Yahoo Finance, MSN, The Motley Fool, and many other publications. A graduate of Southwestern University, he studied business with a focus on investments and has previous experience in banking and startups.
When not reading or writing the news, he is following his passion for Lacrosse, playing chess, or building solar projects with his dad.
